Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep1058 | Thyroid (non-cancer) | ECE2016

Relapse subacute thyroiditis: atypical symptoms

Peretianu Dan , Carsote Mara , Voicu Gabriela , Neamtu Daniela , Goldstein Andrei , Valea Ana

Introduction: Subacute thyroiditis (ST) is a self limited condition; relapse is rarely seen. Anterior cervical complains and inflammatory syndrome is highly suggestive.Aim: We report a series of female cases associating arelapse of ST which was confirmed after the admission for atypical distant symptoms as diffuse headache or ear pain.Material and Methods: The endocrine profile is presented.Results: A 48-year...

ea0041ep1074 | Thyroid (non-cancer) | ECE2016

What is the cut-off level for commercial kits for antithyroperoxydase antibody

Carsote Mara , Ratcu Mihaela , Gharibafshar Payman , Paduraru Denis , Staicu Dana Cristina , Peretianu Dan

Aim: The biological diagnostic of Hashimoto thyroiditis (HT) is based on higher than normal levels of antithyroperoxydase antibodies (ATPO). Our goal was to establish the cut-off limit of normality (the upper limit) for ATPO in our thyroid normal patients. This limit and not that of the laboratory, should be used as diagnosis of Hashimoto thyroiditis.Material and method: 1. ATPO was investigated in patients with normal level of thyroid hormones (euthyroi...

ea0037ep145 | Reproduction, endocrine disruptors and signalling | ECE2015

Analysing by decade, testosterone undecanoate depot injectable does not increase prostate volume: study during up to 7 years on hypogonadic patients

Pisoschi Matei , Carsote Mara , Poiana Catalina , Staicu Dana Cristina , Peretianu Dan

Aim: Re-analysing the effect of injectable testosterone undecanoate depot (TUD) in hypogonadic patients.Materials and method: (A) Patients: at onset 210 men with hypogonadism (median age: 61.5 years). (B) Distribution: by decade; n=4, 12, 21, 54, 59, 43, 16, and 1. (C) TUD (NebidoR-Bayer-Schering) 1000 mg was injected one per 3 months i.m. (D) Prostate volume (PV) appreciated by per-abdominal ultrasound: 3.5 MHz probe, elliptical volume (cm...

ea0037ep146 | Reproduction, endocrine disruptors and signalling | ECE2015

Testosterone undecanoate 1000 mg at 3 months did not increased prostatic specific antigen level: January 2015

Pisoschi Matei , Carsote Mara , Poiana Catalina , Staicu Dana Cristina , Peretianu Dan

Aim: To find if testosterone undecanoate (TUD) 1000 mg injection (NebidoR; Bayer-Schering) at 3 months has a negative effect on prostate.Materials and method: i) PSA (ng/ml) registred before (T0) and after TUD at T1 (2 weeks) to T10 (7 years) (see Pisoschi, this Congress); ii) statistical analysis: t-test, simple correlation, and multiple regression.Results: (A) Patients at onset: 143 men, 18–96 years, average: 60.38;...

ea0035p689 | Male reproduction | ECE2014

Analysing by decade, testosterone undecanoat depot injectable does not increases prostate volume: study during up to 6 years on hypogonadic patients

Pisoschi Matei , Carsote Mara , Poiana Catalina , Staicu Cristina Daniela , Peretianu Dan

Aim: Re-analyzing the effect of injectable testosterone undecanoat depot (TUD) in hypogonadic patients.Materials & methods: (A) Patients: at onset 191 men with hypogonadism (median age: 64 years). (B) Distribution: by decade. (C) TUD (NebidoR-Bayer-Schering) 1000 mg was injected one per 3 months i.m. (D) Prostate volume (PV) by per-abdominal ultrasound: 3.5 MHz probe, elliptical volume (cm3), Aloka 550. (E). Time of analysis: be...

ea0035p969 | Thyroid (non-cancer) | ECE2014

Evolution of thyroid function in Hashimoto's thyroiditis and related disorders–January 2014

Poiana Catalina , Carsote Mara , Staicu Cristina Daniela , Clodeanu Alexandrina , Peretianu Dan

Aim: Analyzing the evolution of thyroid function in thyroiditis and related disease between 1–20 years.Material and method: i). Diagnostic: Hashimoto thyroiditis (HT): 1. antithyroperoxydase antibodies (ATPO), cut-off 34 ui/ml. 2. if ATPO=normal, thyroiditis was considered if high antithyroglobuline antibodies (T-ATG); 3. idiopathic mixedema (IM): hypothyroidism with no ATPO, no A...

ea0035p970 | Thyroid (non-cancer) | ECE2014

Immune associations in chronic thyroiditis – January 2014

Carsote Mara , Poiana Catalina , Staicu Cristina Daniela , Clodeanu Alexandrina , Peretianu Dan

Material and method: i). Patients: A. ‘Classical’ Hashimoto thyroiditis (hyper-ATPO-emia, HT) =1293, B. thyroiditis with isolated hyper-ATG-emia, with normal ATPO (T-ATG) =92, C. thyroiditis ‘sero-negative’ (normal ATPO and ATG, pathology diagnosis) =11, D. idiopathic myxedema (hypothyroidism, no A,B,C) =86; E. control=1219. 2. Statistical analysis: X2 test, z test.Results:...

ea0035p971 | Thyroid (non-cancer) | ECE2014

Relationships between antithyroperoxydase antibody and antithyroglobulin antibody levels with thyroid function in chronic thyroiditis – January 2014

Carsote Mara , Poiana Catalina , Daniela S Cristina , Clodeanu Alexandrina , Peretianu Dan

Aim and Objectives: Is Hashimoto thyroiditis (HT) different from thyroiditis with only antithyroglobulin antibodies (T-ATG)?Material and method: i). Diagnosis: ATPO >34 ui/ml = HT; ATPO normal with high ATG (>34 ui/ml) =T-ATG. ii). Thyroid function: TSH. iii). Patients: HT=1293, T-ATG=92. iv). Statistical analysis: Student tα, linear correlation tests....

ea0032p554 | Endocrine tumours and neoplasia | ECE2013

The adverse effects in sub-optimal mitotane doses: a retrospective study

Baloescu Rene , Petris Rodica , Peretianu Dan , Dumitrascu Anda , Miron Roxana , Paun Sorin , Carsote Mara , Poiana Catalina

Introduction: There are many side effects caused by mitotane and several are registered at drug levels lower than therapeutical doses.Aim: We observed the mitotane side effects in patients treated for adrenal cancer.Materials and methods: This is a retrospective study in adrenal tumors.Results: Out of 56 patients included in a database with adrenal tumors, we found eight patients (14.25%) with adrenal cancer ...

ea0032p663 | Male reproduction | ECE2013

Analysing by decade, testosterone undecanoat depot injectable does not increases prostate volume. Study during up to 6 years on hypogonadic patients

Peretianu Dan , Carsote Mara , Poiana Catalina , Cristina Staicu Daniela , Pisoschi Matei

Aim: Re-analyzing the effect of injectable testosterone undecanoat depot (TUD) in hypogonadic patients.Material-method: i) Patients: at onset 175 men with hypogonadism (median age: 64 years). ii) Distribution: by decade. iii) TUD (Nebido-Bayer-Schering) 1000 mg was injected one per 3 months i.m. iv) Prostate volume (PV) appreciated by per-abdominal ultrasound: 3.5 MHz probe, elliptical volume (cm3), Aloka 550. v) Time of analysis: before start...